CD8A and prostate carcinoma: In prostate cancer, Han and colleagues found that Erdafitinib treatment combined with S100A11 knockdown in PCa cells and CAFs increased infiltration of effective CD8+ T cells in the tumor, thereby reducing tumorigenicity (Figure 3A) [107].